About: Saratoga Opthalmology

Posts by Saratoga Opthalmology:

Alert: Possible shortage of epinephrine for intraocular use

A recent alteration in the formulation of preservative-free epinephrine could lead to a shortage of mydriatic agents for ophthalmologists, according to an alert issued by the American Society of Cataract and Refractive Surgery (ASCRS). Source: AAO

Posted on: Dec 14 2017
By: Saratoga Opthalmology
Leave a reponse

Novel video goggles offer quick, easy and reliable measurements of ocular deviation

This cross-sectional study examines the utility of strabismus goggles, which feature a head-fixed laser target display and liquid crystal display shutters, for binocular dissociation. Source: AAO

Posted on: Dec 14 2017
By: Saratoga Opthalmology
Leave a reponse

Omidria approved for pediatric patients

The FDA has expanded the indication for Omidria, a mydriatic and NSAID combination agent, to include use in pediatric patients from birth through 17 years. Source: AAO

Posted on: Dec 12 2017
By: Saratoga Opthalmology

Early steroid response predicts long-term vision gains in DME

Findings from this retrospective study suggest that patients with initial suboptimal response to an intravitreal corticosteroid implant may continue to have a suboptimal response on long-term follow-up. Source: AAO

Posted on: Dec 11 2017
By: Saratoga Opthalmology

Retrospective study finds MRSA in nearly half of eyebrow infections

This study reviews the bacterial origins and potential causative factors of preseptal cellulitis and abscesses involving the eyebrow. Source: AAO

Posted on: Dec 11 2017
By: Saratoga Opthalmology

Week in review: Eye glue, facial hygiene, omega-3 eyedrops

This week researchers unveil a temperature-sensitive sealant that could buy time for open-globe injuries, and an omega-3-supplemented eye drop gets approved in Europe. Source: AAO

Posted on: Dec 9 2017
By: Saratoga Opthalmology

Zika vaccine advances to phase 2 testing

A new Zika vaccine shows promising safety and immunogenicity, according to a phase 1 trial by the Vaccine Research Center at the NIH. Source: AAO

Posted on: Dec 8 2017
By: Saratoga Opthalmology

Reproxalap on track to supplant steroids for patients with uveitis

Physicians may soon have a steroid alternative in their uveitis treatment toolkit: A phase 2 trial finds that the new aldehyde trap drug reproxalap (Aldeyra Therapeutics) is noninferior to prednisolone acetate (Pred Forte) at reducing ocular inflammation in patients with noninfectious anterior uveitis. Source: AAO